JCT  Vol.6 No.9 , September 2015
Immunohistochemical Expression of VEGF in Relation to Other Pathological Parameters of Breast Carcinoma
Author(s) Mais Almumen
ABSTRACT
Background: Several molecular markers have been detected that are important in clinical aspect of malignancies especially in breast cancer. More recently, the expression of vascular endothelial growth factor (VEGF), the most potent endothelial cell mitogen and also a regulator of vascular permeability, is emerging as a prognostic marker in patients with several types of cancer including breast cancer. This study assessed the expression of VEGF in a series of breast cancers in correlation with HER-2/neu and steroid receptors (ER and PR) in standard clinicopathological parameters in an attempt to clarify its potential clinical importance in Iraqi females of Middle Euphrates area. Findings: The present investigation was performed over a period starting from September 2011 through September 2012. Formalin-fixed, paraffin-embedded blocks from 52 patients with breast cancer (44 ductal and 8 lobular carcinoma) were included in this study. A group of 20 patients with fibroadenoma was included as a comparative group, and 20 samples of normal breast tissue sections were used as controls. Labeled streptavidin-biotin (LSAB+) complex method was employed for immunohistochemical detection of VEGF, HER-2/neu, ER and PR. The detection rate of VEGF, HER-2/neu, ER and PR was 59.62%, 36.96%, 34.62% and 36.54% respectively. There was a significant difference in immunoexpression between ductal and lobular carcinoma, but not significantly different among tumor sizes, tumor grades, axillary lymph node involvement and age of the patients. However, VEGF was positively correlated with tumor grade, tumor size, nodal involvement and HER-2/neu, but negatively correlated with ER and PR, which show the most unfavorable biopathological profile. Conclusion: VEGF overexpression play an important role in pathogenesis of breast carcinoma evolution, as its positivity associated with biologically aggressive tumors, so incorporation of this biomarker with other parameters into a prognostic index will more accurately predict clinical outcome and determine the effects of anti cancer therapy.
KEYWORDS
Breast Carcinoma, VEGF, ER, PR, IHC

Cite this paper
Almumen, M. (2015) Immunohistochemical Expression of VEGF in Relation to Other Pathological Parameters of Breast Carcinoma. Journal of Cancer Therapy, 6, 811-820. doi: 10.4236/jct.2015.69089.
References
[1]   Singhal, H., Gohel, M.S., Kaur, K. and Thomson, S. (2008) Breast Cancer Evaluation. eMedicine Journal Specialty, 2-10.

[2]   Folkman, J. and Klagsbrun, M. (1987) Angiogenic Factors. Science, 235, 442-447.
http://dx.doi.org/10.1126/science.2432664

[3]   Folkman, J. (1989) What Is the Evidence that Tumors Are Angiogenesis Dependent? Journal of the National Cancer Institute, 82, 4-6.
http://dx.doi.org/10.1093/jnci/82.1.4

[4]   Drovak, H.F., Brown, L.F., Detmar, M. and Dvorak, A.M. (1995) Vascular Permeability Factor/Vascular Endothelial Growth Factor, Microvascular Hyperpermeability, and Angiogenesis. American Journal of Pathology, 146, 1029-1039.

[5]   Ferrara, N. and Alitalo, K. (1999) Clinical Application of Angiogenic Growth Factors and Their Inhibitors. Nature Medicine, 5, 1359-1364.
http://dx.doi.org/10.1038/70928

[6]   Nicosia, R.F. (1998) What Is the Role of Vascular Endothelial Growth Factor-Related Molecules in Tumor Angiogenesis? The American Journal of Pathology, 153, 11-16.
http://dx.doi.org/10.1016/S0002-9440(10)65539-3

[7]   Jung, L., Balan, B.J., Rózewska, E.S., Wynimko, J.C., Siwicki, A.K., Sommer, E., et al. (2007) Clinical Immunology VEGF in Circulating Blood of Patients Treated with Enoxaparine after Orthopaedic Surgery. Central European Journal of Immunology, 32, 61-65.

[8]   Ferrara, N. (1999) Molecular and Biological Properties of Vascular Endothelial Growth Factor. Journal of Molecular Medicine, 77, 527-543.
http://dx.doi.org/10.1007/s001099900019

[9]   Linderholm, B., Tavelin, B. and Grankvist, K. (1998) Vascular Endothelial Growth Factor is of High Prognostic Value in Node-Negative Breast Carcinoma. Journal of Clinical Oncology, 16, 3121-3128.

[10]   Linderholm, B., Lindh, B., Tavelin, B., Grankvist, K. and Henriksson, R. (2000) p53 and Vascular-Endothelial-Growth-Factor (VEGF) Expression Predicts Outcome in 833 Patients with Primary Breast Carcinoma. International Journal of Cancer, 89, 51-62.
http://dx.doi.org/10.1002/(SICI)1097-0215(20000120)89:1<51::AID-IJC9>3.0.CO;2-8

[11]   Toi, M., Hoshina, S. and Takayanagi, T. (1994) Association of Vascular Endothelial Growth Factor Expression with Tumor Angiogenesis and with Early Relapse in Primary Breast Cancer. Japanese Journal of Cancer Research, 85, 1045-1049.
http://dx.doi.org/10.1111/j.1349-7006.1994.tb02904.x

[12]   Toi, M., Inada, K., Suzuki, H. and Tominaga, T. (1995) Tumor Angiogenesis in Breast Cancer. Breast Cancer Research and Treatment, 36, 193-204.
http://dx.doi.org/10.1007/BF00666040

[13]   Valkovic, T., Dobrila, F., Melato, M., Sasso, F., Rizzardi, C. and Jonjic, N. (2002) Correlation between Vascular Endothelial Growth Factor, Angiogenesis, and Tumor-Associated Macrophages in Invasive Ductal Breast Carcinoma. Virchows Archiv, 440, 583-588.
http://dx.doi.org/10.1007/s004280100458

[14]   Wang, F., Wei, L. and Chen, L. (2000) The Relationship between Vascular Endothelial Growth Factor, Microvascular Density, Lymph Node Metastasis and Prognosis of Breast Carcinoma. Chinese Journal of Pathology, 29, 172-175.

[15]   MacConmara, M., O’Hanlon, D.M., Kiely, M.J., Connolly, Y., Jeffers, M. and Keane, F.B. (2002) An Evaluation of the Prognostic Significance of Vascular Endothelial Growth Factor in Node Positive Primary Breast Carcinoma. International Journal of Oncology, 20, 717-721.
http://dx.doi.org/10.3892/ijo.20.4.717

[16]   Ferrara, N. and Henzel, W.J. (1989) Pituitary Follicular Cells Secrete a Novel Heparin-Binding Growth Factor Specific for Vascular Endothelial Cells. Biochemical and Biophysical Research Communications, 84, 856-861.
http://dx.doi.org/10.1016/0006-291x(89)92678-8

[17]   World Health Organization International Agency for Research on Cancer (2003) World Cancer Report, 335.

[18]   Apple, S.K., Hecht, J.R., Lewin, D.N., Jahromi, S.A., Grody, W.W. and Nieberg, R.K. (1999) IHC Evaluation of K-ras, P53, and Her2/neu Expression in Hyperplasic, Dysplastic, and Carcinomatous Lesions of the Pancreas: Evidence for Multistep Carcinogenesis. Human Pathology, 30, 123-129.
http://dx.doi.org/10.1016/S0046-8177(99)90265-4

[19]   Truls, G., Kennet, W. and Jorgen, C. (2005) Analysis of Her2/neu Expression in Primary Bladder Carcinoma and Corresponding Metastases. Journal of Pathology, 95, 982-986.

[20]   (2011) Dakocytomation Catalog for Products and Services. Dako, Glostrup, 139-143.

[21]   Elston, C.W. and Ellis, I.O. (1991) Pathological Prognostic Factors in Breast Cancer. I. The Value of Histological Grade in Breast Cancer: Experience from a Large Study with Long-Term Follow-Up. Histopathology, 19, 403-410.
http://dx.doi.org/10.1111/j.1365-2559.1991.tb00229.x

[22]   Gasparini, G., Toi, M., Miceli, R., Vermeulen, P.B., Dittadi, R., Biganzoli, E., et al. (1999) Clinical Relevance of VEGF and Thymidine Phosphorelase in Patients with Node-Positive Breast Cancer Treated with Either Adjuvant Chemotherapy or Hormone Therapy. The Cancer Journal from Scientific American, 5, 101-112.

[23]   Sorli, T., Perou, C.M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., et al. (2001) Gene Expression Patterns of Breast Carcinomas Distinguishes Tumor Subclasses with Clinical Implication. Proceedings of the National Academy of Sciences of the United States of America, 98, 10869-10874.
http://dx.doi.org/10.1073/pnas.191367098

[24]   Allred, D.C., Harvey, J.M., Berardo, M. and Clark, G.M. (1998) Prognostic and Predictive Factors in Breast Cancer by Immunohistochemical Analysis. Modern Pathology, 11, 155-168.

[25]   Granato, A.M., Nanni, O., Falcini, F., Folli, S., Mosconi, G., Paola, F.D., et al. (2004) bFGF and VEGF Serum Levels in Breast Cancer Patients and Healthy Women. Breast Cancer Research, 6, R38-R45.
http://dx.doi.org/10.1186/bcr745

[26]   Li, J., Song, S.T., Jiang, Z.F., Liu, X.Q. and Yan, L.D. (2003) Significance of Microvascular Density and VEGF in Breast Cancer. Chinese Journal of Oncology, 25, 145-153.

[27]   Ihemelandu, C.U., Leffall, L.D., Naab, T.J. and Fredrieck, W.A. (2007) Expression of VEGF, p53 in Molecular Breast Cancer Subtypes of Pre-Menopausal African-American Women. Journal of Clinical Oncology, 25.

[28]   Matkowski, R., Gisterek, I., Suder, E., Lacko, A., Szelachowska, J., Ramsey, D. and Kornafel, J. (2006) Correlation between VEGF and C-Met Expressions in Breast Carcinoma. Journal of Clinical Oncology, 24.

[29]   Elli, I., Charchanti, A., Briasoulis, E., Karavasilis, V., Batsis, C., Pavlidis, N., et al. (2002) The Prognostic Value of Vascular Endothelial Growth Factor (VEGF) in Invasive Breast Cancer: Correlation with Microvessel Density (MVD), ER, PgR, p53 and Proliferative Associated Indices (Ki-67, PCNA). Electronic Journal of Pathology and Histology, 8, 024-007.

[30]   Harmey, J.H. and Bouchier-Hayes, D. (2002) VEGF, a Survival Factor for Tumour Cells: Implications for Anti-Angiogenic Theraoy. Bioassays, 24, 280-283.
http://dx.doi.org/10.1002/bies.10043

[31]   Bachelder, R.E., Crago, A., Chung, J., Wendt, M.A., Shaw, L.M., Robinson, G. and Mercurio, A.M. (2001) VEGF Is an Autocrine Survival Factor for Neuropilin-Expressing Breast Carcinoma Cells. Cancer Research, 61, 5736-5776.

[32]   Halimi, M., Vahedi, A. and Mostafapour, E.K. (2012) Association of VEGF with Regional Lymph Node Metastasis in Breast IDC. Journal of Medical Sciences, 12, 18-23.
http://dx.doi.org/10.3923/jms.2012.18.23

[33]   Xu, W., Wang, G., Zou, Y., Song, J., Yang, X. and Wang, W. (2007) VEGF Expression in IDC of Breast. Chinese Journal of Cancer Research, 19, 56-59.
http://dx.doi.org/10.1007/s11670-007-0056-y

[34]   Bolat, F., Kayaselcuk, F., Nursal, T.Z., Yagmurdur, M.C., Bal, N. and Demirhan, B. (2006) Microvessel Density, VEGF Expression, and Tumor Associated Macrophages in Breast Tumors. Journal of Experimental & Clinical Cancer Research, 25, 365-437.

[35]   Macolm, M., Deidre, O.M., James, K.M., Yvonne, C., Michael, J. and Keane, F.B. (2002) An Evaluation of the Prognostic Significance of VEGF in Node Positive Primary Breast Carcinoma. The Internet Journal of Oncology, 20, 717-721.

[36]   Gasparini, G., Toi, M., Gion, M., Verderio, P., Dittadi, R., Hanatani, M., et al. (1997) Prognostic Significance of VEGF Protein in Node-Negative Breast Carcinoma. Journal of the National Cancer Institute, 89, 139-186.
http://dx.doi.org/10.1093/jnci/89.2.139

[37]   Hao, L., Zhang, C., Qiu, Y., Wang, L., Luo, Y., Jin, M., et al. (2007) Recombination of CXCR4, VEGF, and MMP-9 Predicting Lymph Node Metastasis in Human Breast Cancer. Cancer Letters, 253, 34-42.
http://dx.doi.org/10.1016/j.canlet.2007.01.005

[38]   Wang, X.B., Yang, Q.X. and Pei, X.J. (2006) Expression of Angiogenesis-Related Factors in Invasive Breast Cancer and Its Clinical Significance. Journal of Southern Medical University, 26, 860-863.

[39]   Hu, S.E., Zhang, Y.J., Cui, Y.M. and Zhang, H.Q. (2005) Expression of VEGF-A and -C in Human Breast Cancer and Their Significance. Chinese Journal of Cancer, 24, 1076-1085.

[40]   Yi, W.J., Tang, Z.H., Yang, Z.L., Yu, M.Y., Li, Y.S. and Chen, G.N. (2003) Difference in Expression of VEGF, bFGF and Their Receptors between the Young and Postmenapaosal Women with Breast Cancer. Chinese Journal of Oncology, 25, 141-145.

[41]   Linardou, H., Kalogeras, K.T., Kronenwett, R., Kouvatseas, G., Wirtz, R.M., Zagouri, F., et al. (2012) The Prognostic and Predictive Value of mRNA Expression of Vascular Endothelial Growth Factor Family Members in Breast Cancer: A Study in Primary Tumors of High-Risk Early Breast Cancer Patients Participating in a Randomized Hellenic Cooperative Oncology Group Trial. Breast Cancer Research, 14, R145.
http://dx.doi.org/10.1186/bcr3354

[42]   Fuckar, D., Dekanic, A. and Stifter, S. (2006) VEGF and Other Common Tumor Markers in Breast Cancer. International Journal of Surgical Pathology, 14, 49-55.
http://dx.doi.org/10.1177/106689690601400109

[43]   Konecny, G.E., Meng, Y.G., Untch, M., Wang, H.J., Bauerfeind, I., Epstein, M., Stieber, P., et al. (2004) Association between HER-2/neu and VEGF Expression Predicts Clinical Outcome in Primary Breast Cancer Patients. Clinical Cancer Research, 10, 1706-1716.
http://dx.doi.org/10.1158/1078-0432.CCR-0951-3

[44]   Yavuz, S., Paydas, S., Disel, U., Zorludemir, S. and Erdogan, S. (2005) VEGF-C Expression in Breast Cancer: Clinical Importance. Advances in Therapy, 22, 368-380.
http://dx.doi.org/10.1007/BF02850084

[45]   Buteau-Lozano, H., Ancelin, M. and Lardeux, B. (2002) VEGF and Other Common Tumor Markers in Breast Cancer. Cancer Research, 62, 4977-4984.

[46]   Sarah, P.G., Margaret, J.C., Cheng, H., et al. (2000) The Short Form of the Alternatively Spliced Flt-4 but Not Its Ligand Vascular Endothelial Growth Factor C Is Related to Lymph Node Metastasis in Human Breast Cancers. Clinical Cancer Research, 6, 4278-4286.

[47]   Dakocytomation General Instructions for Immunohistochemical Staining: Manual instructions to the Universal Dakocytomation, LSAB, Dako, Denmark, 2004.

 
 
Top